Intelligence Feed event · Policy · 2026-09-09

    CRISPR Therapeutics Expands Casgevy Label to Pediatric Patients as Q2 Sales Hit $76M

    Question

    CRISPR Therapeutics Expands Casgevy Label to Pediatric Patients as Q2 Sales Hit $76M

    Direct answer

    CRISPR Therapeutics recorded $76 million in second-quarter Casgevy revenue, marking a 78% sequential increase as commercial adoption scales in sickle cell disease and transfusion-dependent beta-thalassemia. Commercial upside was reinforced by FDA approval expanding Casgevy's indication to pediatric patients aged two and older, widening the eligible commercial population and providing durable therapy uptake across specialized treatment centers.

    Original publisher
    Market Ontology
    Evidence through
    2026-09-09
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “CRISPR Therapeutics Expands Casgevy Label to Pediatric Patients as Q2 Sales Hit $76M”, revision 1, evidence through 2026-09-09. https://marketontology.com/market-events/2026-09-09/crispr-therapeutics-expands-casgevy-label-to-pediatric-patients-as-q2-sales-hit-1c4fe5

    POLICY
    CRISPR Therapeutics Expands Casgevy Label to Pediatric Patients as Q2 Sales Hit $76M
    CRISPR Therapeutics recorded $76 million in second-quarter Casgevy revenue, marking a 78% sequential increase as commercial adoption scales in sickle cell disease and transfusion-dependent beta-thalassemia. Commercial upside was reinforced by FDA approval expanding Casgevy's indication to pediatric patients aged two and older, widening the eligible commercial population and providing durable therapy uptake across specialized treatment centers.
    CRSPVRTX
    Impact
    66
    SEP 9
    SIG
    90%
    CRSPVRTX
    CRISPR Therapeutics Expands Casgevy Label to Pediatric Patients as Q2 Sales Hit $76M
    CRISPR Therapeutics recorded $76 million in second-quarter Casgevy revenue, marking a 78% sequential increase as commercial adoption scales in sickle cell disease and transfusion-dependent beta-thalassemia. Commercial upside was reinforced by FDA approval expanding Casgevy's indication to pediatric patients aged two and older, widening the eligible commercial population and providing durable therapy uptake across specialized treatment centers.
    → FDA pediatric label expansion broadens the addressable patient pool for Casgevy, increasing recurring royalty and commercial revenue streams for CRSP and partner Vertex.
    Impact
    CRISPR Therapeutics recorded $76 million in second-quarter Casgevy revenue, marking a 78% sequential increase as commercial adoption scales in sickle cell disease and transfusion-dependent beta-thalassemia. Commercial upside was reinforced by FDA approval expanding Casgevy's indication to pediatric patients aged two and older, widening the eligible commercial population and providing durable therapy uptake across specialized treatment centers.
    Affected
    CRSPVRTX
    Transmission
    FDA pediatric label expansion broadens the addressable patient pool for Casgevy, increasing recurring royalty and commercial revenue streams for CRSP and partner Vertex.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    CRSPcommercial revenue acceleration via pediatric label expansionUp1-3mCasgevy revenue rose 78% QoQ to $76M with FDA approval for ages 2 and up.
    VRTXcommercial partnership royalty and revenue sharing upsideUp1-3mVertex co-develops and commercializes Casgevy globally with CRISPR Therapeutics.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    AssetCallBase close+1 day+5 days+20 days
    VRTXUpdisagreed521.12 2026-09-09-1.26%-1.51%Pending

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month